poisar

Stock

Trevi Therapeutics, Inc. TRVI

$18.11+0.98%

Overview

TRVI market data

Price History

TRVI price chart · 1M
O
17.65
H
18.11
L
17.63
C
18.11
Vol
33,975.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$17.65
Previous Close
$17.93
Day High
$18.11
Day Low
$17.63
52 Week High
$20.14
52 Week Low
$13.13
7 Day Return
-0.85%
30 Day Return
-1.76%
90 Day Return
+28.04%
1 Year Return
+31.01%
Daily Notional Volume
$615.1K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.32
Diluted earnings per share over the trailing twelve months.
Beta
0.92
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$6.93 – $20.22
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $2.6B · P/B 8.76.

Company News

10 captured
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28Benzinga · Aug 14, 2026, 12:52 PM
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25Benzinga · Aug 7, 2026, 3:21 PM
Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30Benzinga · Aug 7, 2026, 12:09 PM
Trevi Therapeutics Q2 EPS $(0.11), InlineBenzinga · Aug 6, 2026, 8:12 PM
Trevi Therapeutics to Participate in Upcoming August ConferencesGlobenewswire Inc · Jul 28, 2026, 12:15 PM
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga · Jul 21, 2026, 3:14 PM
Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.Benzinga · Jul 21, 2026, 2:32 PM
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 21, 2026, 11:58 AM
BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36Benzinga · Jul 21, 2026, 10:06 AM
B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31Benzinga · Jul 20, 2026, 1:36 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock